ES2570994T3 - Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer - Google Patents
Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncerInfo
- Publication number
- ES2570994T3 ES2570994T3 ES06844324T ES06844324T ES2570994T3 ES 2570994 T3 ES2570994 T3 ES 2570994T3 ES 06844324 T ES06844324 T ES 06844324T ES 06844324 T ES06844324 T ES 06844324T ES 2570994 T3 ES2570994 T3 ES 2570994T3
- Authority
- ES
- Spain
- Prior art keywords
- 4alkyl
- 5alkyl
- substituted
- 3alkoxy
- amidino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002660 stem cell treatment Methods 0.000 title 1
- -1 amino, amidino, guanidino, hydrazino Chemical group 0.000 abstract 29
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73465505P | 2005-11-08 | 2005-11-08 | |
| PCT/US2006/043859 WO2007056593A2 (en) | 2005-11-08 | 2006-11-08 | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2570994T3 true ES2570994T3 (es) | 2016-05-23 |
Family
ID=37890190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06844324T Active ES2570994T3 (es) | 2005-11-08 | 2006-11-08 | Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20070129353A1 (enExample) |
| EP (1) | EP1957516B1 (enExample) |
| JP (1) | JP5536336B2 (enExample) |
| KR (1) | KR101486490B1 (enExample) |
| AU (1) | AU2006311433B2 (enExample) |
| CA (1) | CA2629136C (enExample) |
| ES (1) | ES2570994T3 (enExample) |
| WO (1) | WO2007056593A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080657B2 (en) * | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7566711B2 (en) * | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7232822B2 (en) * | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| JP2009538903A (ja) * | 2006-05-30 | 2009-11-12 | チュンウェ ファーマ コーポレーション | 幹細胞分化の誘導または抑制のための組成物 |
| EP2783700A1 (en) * | 2006-09-07 | 2014-10-01 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
| AU2008325219A1 (en) * | 2007-11-05 | 2009-05-14 | Puretech Ventures | Methods, kits, and compositions for administering pharmaceutical compounds |
| RU2512538C2 (ru) | 2008-06-06 | 2014-04-10 | Присм Байолэб Корпорейшн | Альфа-спиральные миметики и способы, связанные с ними |
| WO2010001989A1 (ja) * | 2008-07-03 | 2010-01-07 | 協和発酵キリン株式会社 | 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤 |
| US20100022549A1 (en) * | 2008-07-23 | 2010-01-28 | The Scripps Research Institute | Alpha-helix mimetic with functionalized pyridazine |
| JP5816087B2 (ja) * | 2008-08-29 | 2015-11-18 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｓｍｏアンタゴニストとしての飽和二環式複素環誘導体 |
| WO2010030948A2 (en) * | 2008-09-12 | 2010-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies |
| US8691819B2 (en) | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| AU2010237633B2 (en) * | 2009-04-15 | 2015-09-17 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| EP2427451B1 (en) | 2009-05-07 | 2019-03-20 | PRISM BioLab Co., Ltd. | Alpha helix mimetics and methods relating thereto |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| JPWO2011096440A1 (ja) | 2010-02-03 | 2013-06-10 | 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ | 天然変性タンパク質に結合する化合物およびそのスクリーニング方法 |
| US20130231385A1 (en) | 2010-05-28 | 2013-09-05 | The Board Of Regents Of The University Of Texas Systems | Oligo-benzamide compounds and their use |
| KR101892575B1 (ko) | 2010-10-14 | 2018-08-31 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
| JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| JP2014509298A (ja) | 2011-02-25 | 2014-04-17 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | アルファへリックスミメティック及びその関連の方法 |
| WO2012168167A1 (en) | 2011-06-09 | 2012-12-13 | F. Hoffmann-La Roche Ag | Method for differentiation of pluripotent stem cells into vascular bed cells |
| US8835493B2 (en) | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
| US8754124B2 (en) | 2011-11-23 | 2014-06-17 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| CN105899211A (zh) | 2013-10-18 | 2016-08-24 | 小路弘行 | 使用cbp/连环蛋白的抑制剂治疗肝纤维化 |
| EP3150207B1 (en) | 2014-03-28 | 2019-12-25 | National University Corporation Tottori University | Inhibitory effect of low molecular weight compound on cancer and fibrosis |
| CA2988707C (en) * | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| EP3841197A1 (en) | 2018-08-21 | 2021-06-30 | F. Hoffmann-La Roche AG | Methods for assessing transendothelial barrier integrity |
| EP3867358A1 (en) | 2018-10-19 | 2021-08-25 | F. Hoffmann-La Roche AG | Synergistic transcription factors to induce high resistance transendothelial barrier |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| AU2021358007A1 (en) * | 2020-10-05 | 2023-06-01 | Genesis Molecular Technologies, Inc. | Topical agents for dermatological applications |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929237A (en) * | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6294525B1 (en) * | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US7008941B2 (en) * | 2001-05-16 | 2006-03-07 | Myriad Genetics, Inc. | Reverse-turn mimetics and methods relating thereto |
| US7232822B2 (en) | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7576084B2 (en) | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| ATE398129T1 (de) * | 2001-10-12 | 2008-07-15 | Choongwae Pharma Corp | Reverse-turn-mimetika und diese betreffendes verfahren |
| US7566711B2 (en) | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| WO2004035587A1 (en) * | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7390814B2 (en) * | 2003-02-13 | 2008-06-24 | Sanofi-Aventis Deutschland Gmbh | Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments |
| ATE472548T1 (de) | 2003-02-13 | 2010-07-15 | Sanofi Aventis Deutschland | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| WO2005021025A2 (en) * | 2003-08-28 | 2005-03-10 | Choongwae Pharma Corporation | MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION |
| US7563825B1 (en) | 2005-03-18 | 2009-07-21 | Choongwae Pharma Corporation | Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation |
| AU2006227776A1 (en) * | 2005-03-18 | 2006-09-28 | Institute For Chemical Genomics | Alpha-helix mimetics and methods relating to the treatment of fibrosis |
-
2006
- 2006-11-08 US US11/594,576 patent/US20070129353A1/en not_active Abandoned
- 2006-11-08 AU AU2006311433A patent/AU2006311433B2/en active Active
- 2006-11-08 CA CA2629136A patent/CA2629136C/en active Active
- 2006-11-08 WO PCT/US2006/043859 patent/WO2007056593A2/en not_active Ceased
- 2006-11-08 EP EP06844324.1A patent/EP1957516B1/en active Active
- 2006-11-08 JP JP2008540227A patent/JP5536336B2/ja active Active
- 2006-11-08 KR KR1020087013755A patent/KR101486490B1/ko active Active
- 2006-11-08 ES ES06844324T patent/ES2570994T3/es active Active
-
2009
- 2009-11-11 US US12/616,712 patent/US8293743B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006311433A1 (en) | 2007-05-18 |
| US20070129353A1 (en) | 2007-06-07 |
| CA2629136C (en) | 2016-03-08 |
| KR20080070060A (ko) | 2008-07-29 |
| AU2006311433B2 (en) | 2012-06-28 |
| KR101486490B1 (ko) | 2015-01-27 |
| US20100069333A1 (en) | 2010-03-18 |
| CA2629136A1 (en) | 2007-05-18 |
| WO2007056593A3 (en) | 2007-07-12 |
| WO2007056593A2 (en) | 2007-05-18 |
| JP5536336B2 (ja) | 2014-07-02 |
| EP1957516B1 (en) | 2016-03-09 |
| EP1957516A2 (en) | 2008-08-20 |
| US8293743B2 (en) | 2012-10-23 |
| JP2009515890A (ja) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20027480A (es) | Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA200400361A1 (ru) | Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv | |
| NO20043587L (no) | Nye heterocykliske forbindelser som er aktive som inhibitorer av beta-laktamaser | |
| EA201170176A1 (ru) | Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента | |
| HN2009001262A (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5) | |
| CL2010001486A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras. | |
| EA201100928A1 (ru) | Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов | |
| CY1106358T1 (el) | Νεοι δικυκλικοι αναστολεις της ορμονοευαισθητης λιπασης | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| EA201270046A1 (ru) | Новые производные фенилимидазола в качестве ингибиторов фермента pde10a | |
| EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
| CO6541547A2 (es) | Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek | |
| EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| EA200801287A1 (ru) | Пиримидиновые производные для лечения аномального клеточного роста | |
| MX2009010302A (es) | Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion. | |
| CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| EA200600227A1 (ru) | Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов | |
| EA200970041A1 (ru) | Ингибиторы акт (протеинкиназы в) | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
| CR11824A (es) | Derivados heterocíclicos de la urea y sus métodos de empleo | |
| EA201170595A1 (ru) | ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА | |
| PA8589801A1 (es) | Aminoalcoxiindoles |